MRC Technology and AstraZeneca are launching an initiative to find new epigenetic drug targets in respiratory disease. They are now seeking academics with relevant epigenetics targets to collaborate with them to develop novel treatments for respiratory diseases, which affect millions of people every year.15 June 2016
MRC Technology and Keio University to collaborate on drug discovery
19 May London (UK) and Tokyo (Japan) MRC Technology and Keio University School of Medicine have signed a memorandum of understanding outlining their collaboration to identify promising antibody and small molecule research and translate them into early stage assets. By combining capabilities, the partnership aims to accelerate discovery to a stage where it is ready for clinical development by pharmaceutical companies and ultimately benefit patients.
MRC Technology, a medical research charity, aims to find treatments in areas of unmet patient needs. It offers commercialisation and intellectual property (IP) management skills and diagnostic and drug discovery expertise, specialising in small molecules and therapeutic antibodies.
Keio University is a modern institution found on ‘jitsugaku’ (science) based learning. It has developed expertise in a wide range of therapeutic areas, including cancer, cardiovascular and metabolic diseases.
MRC Technology has a similar agreement in place with Tokyo University.19 May 2016
Patent protection for biotech/genetic engineering: report
Andrew Farquarson, Director, Technology Transfer, has been a member of the EU Commission’s Expert Group appointed in 2012 to advise on the Biotech Directive and patent protection for biotech/genetic engineering inventions.
Their report has now been published.
Medical related information are on page 127 (are/should stem cells, including human embryonic stem cells, be patentable ) and page 176 (should patents on nucleic acids be use-limited).18 May 2016
MRC Technology, a medical research charity, has signed an agreement to review DEBRA Austria’s research portfolio, aiming to identify promising projects and results which could be suitable for translation into better treatments.26 April 2016
(Antibody humanised by MRC Technology) Merck, known as MSD outside the United States and Canada, announced that the US Food and Drug Administration (FDA) has awarded Keytruda (pembrolizumab) Breakthrough Therapy Designation in classical Hodgkin Lymphoma. It is the drug’s fourth breakthrough status – previously awarded for advanced melanoma, non-small cell lung cancer and colorectal cancer. Keytruda is considered a next generation drug in cancer care, stimulating the body’s immune system to fight the disease. The therapeutic is one of a new generation of PD-1 (programmed cell death protein… Read More20 April 2016
MRC Technology has completed the move of its Centre for Therapeutics Discovery to state-of-the-art laboratory facilities at the SBC campus. Some teams will also relocate from the central London office. The charity will still have an office in London, along with laboratories and an office in Edinburgh.19 April 2016
MRC Technology, an independent life science medical research charity, has appointed Dr Les Hughes and Dr Mike Romanos to the board of trustees, with effect from 1 March 2016.7 April 2016
MRC Technology and Institut Pasteur of Shanghai, Chinese Academy of Sciences collaborate on antibody drug development
MRC Technology and Institut Pasteur of Shanghai, Chinese Academy of Sciences (IPS-CAS) have signed a collaboration agreement to develop new therapeutic antibodies from research originating in China.6 April 2016
Dementia Consortium welcomes MSD as a new partner in their global venture to accelerate drug discovery for neurodegenerative disease. MSD is the latest pharmaceutical company to join the Dementia Consortium – a £4.5 million charity-industry partnership between Alzheimer’s Research UK, MRC Technology and pharmaceutical companies Abbvie, Astex, Eisai and Lilly.8 March 2016
New dementia drug discovery efforts get underway this month at the University of South Florida, thanks to £875,000 funding from the Dementia Consortium. The US team of academics will work with drug development experts at UK-based MRC Technology, to target the immune system in a bid to halt nerve cell damage.1 March 2016